Methallylescaline

Corrected from the live row’s “Unscheduled” wording. The current federal sources support only a bounded direct-list absence observation plus a conditional analogue warning: 21 U.S.C. § 802(32) defines the legal analogue test, and § 813 applies Schedule I treatment only to an analogue to the extent intended for human consumption. They do not establish that this exact molecule is categorically a federal analogue in every context. Virginia’s current Schedule I text expressly names the exact chemical synonym and Methallylescaline; 2024 Chapter 62, approved March 8, 2024, retained the same entry when reenacting § 54.1-3446. The state finding is material and defeats an unqualified U.S. “Unscheduled” conclusion, but it cannot be generalized to the other states, D.C., territories, or federal law without further research. No federal or state prosecution fact pattern for this exact molecule was located.

The correction is based on an exact German Schedule I listing, not an analogue inference. MAL is the legal schedule synonym for Methallylescaline, and the listed chemical name matches the PubChem identity. Anlage I is the non-marketable narcotics list; ordinary unauthorized possession and dealings are criminal under BtMG § 29, with statutory exceptions and prosecutorial/court discretion not amounting to legalization. The NpSG exclusion for BtMG narcotics means the prior NpSG-only description should be replaced.

The live row's legacy conclusion (Illegal under the Psychoactive Substances Act 2016) is corrected because it omitted the more specific and more restrictive Misuse of Drugs Act classification. Methallylescaline's verified structure is a ring-substituted phenethylamine within Schedule 2 Part I paragraph 1(c), making it Class A, and the matching category in Misuse of Drugs Regulations Schedule 1 paragraph 1(d) governs the regulatory schedule. The legacy statement that personal possession is not criminalized is true only as a description of the Psychoactive Substances Act's standalone offences; it is not a correct overall UK legality conclusion because Misuse of Drugs Act section 5 criminalizes unauthorized possession of a controlled drug. The result is limited to the verified Methallylescaline identity and ordinary unauthorized conduct, subject to statutory licences, regulatory permissions, defences and exceptions.

Methallylescaline (PubChem CID 44350127; CAS 207740-41-8; 2-[3,5-dimethoxy-4-(2-methylprop-2-enoxy)phenyl]ethanamine) is not expressly named in the current consolidated Controlled Drugs and Substances Act schedules. Schedule III item 17 controls mescaline and its salts but does not extend that entry to derivatives or analogues. Methallylescaline also does not meet Schedule III item 35's 2C-phenethylamine threshold: its verified ring substituents are 3,5-dimethoxy and 4-(2-methylprop-2-enoxy), not 2'/5' or 2'/6' alkoxy/haloalkoxy substitution or a listed fused oxygen ring. Although Schedule I's amphetamine entries include analogues, methallylescaline has an alpha-unsubstituted aminoethyl side chain rather than the alpha-methylbenzeneethanamine framework stated for amphetamine; Health Canada's CDSA-based 2022 table separately classifies allylescaline, another mescaline-derived alpha-unsubstituted phenethylamine, as not controlled. The live federal Prescription Drug List had no matching entry, and exact-name, chemical-name and CAS queries of Health Canada's nightly Drug Product Database returned no active-ingredient record. Health Canada documented methallylescaline's detection in Canada but did not state its control status in that report, and no current public substance-specific CSD confirmation was located. Accordingly this is a sourced federal scheduling conclusion, not a claim of general authorization: it does not establish an approved drug product, unrestricted sale or importation, or the absence of provincial or territorial restrictions.

The live Switzerland row is supported, not corrected: it already states that Methallylescaline is specifically named in Swiss Verzeichnis E. The current binding BetmVV-EDI consolidation (stand 13 March 2026) confirms the exact entry as Annex 6 Verzeichnis e no. 149, Methallylescalin, with matching chemical names and CAS 207740-41-8. BetmKV distinguishes Verzeichnis e controlled suspected-narcotic-like materials from Verzeichnis d prohibited controlled substances and assigns EDI operating permits for Verzeichnis-e handling; BetmG Article 7 supplies the authorization basis. Accordingly canonicalStatus is restricted_other, retaining the live controlled designation without upgrading it to the separate Verzeichnis-d prohibited category. Swissmedic's older list-e PDF corroborates the exact row but expressly is not exhaustive; the Fedlex schedule is dispositive.